Showing results (21-30 of 154) with videos related to
Sort By:
Pageof 16
Expert Opinion on Therapeutic Targets|September 11, 2012
LSD1 inhibition: a therapeutic strategy in cancer?James T Lynch, William J Harris, Tim C P SomervailleCell Stem Cell|February 10, 2009
Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cellsTim C P Somervaille, Christina J Matheny, Gary J Spencer, et al.Ejhaem|July 8, 2025
Bleeding Complications in JAK2-Variant Essential Thrombocythemia: A Revisit in 2025Gerard Gurumurthy, Samantha Gurumurthy, Tim C P Somervaille, et al.Hemasphere|November 15, 2019
AXL Inhibition Extinguishes Primitive JAK2 Mutated Myeloproliferative Neoplasm Progenitor CellsStella Pearson, Rognvald Blance, Tim C P Somervaille, et al.Molecular & Cellular Oncology|September 26, 2018
LSD1 inhibitors disrupt the GFI1 transcription repressor complexAlba Maiques-Diaz, James T Lynch, Gary J Spencer, et al.Best Practice & Research. Clinical Haematology|December 5, 2009
Regulating the leukaemia stem cellMichael L ClearyAnalytical Biochemistry|August 6, 2013
CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1James T Lynch, Mark J Cockerill, James R Hitchin, et al.Epigenomics|June 26, 2015
KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative diseaseTamara Maes, Cristina Mascaró, Alberto Ortega, et al.BMC Cancer|October 29, 2021
Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activityMark S Williams, Naseer J Basma, Fabio M R Amaral, et al.Pageof 16